Intellia Therapeutics, Inc. (NTLA) saw its loss widen to $12.63 million, or $0.36 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $6.69 million, or $9.89 a share.

Revenue during the quarter surged 249.75 percent to $6.22 million from $1.78 million in the previous year period.

Operating loss for the quarter was $12.95 million, compared with an operating loss of $6.69 million in the previous year period.

"The first quarter of 2017 has been highly productive for Intellia as we continue to advance our preclinical programs toward developing life-transforming therapies. Building on our earlier results showing 97 percent in vivo reduction of serum transthyretin protein levels, our durability data also continue to demonstrate stable liver editing and support our vision that genome editing could be effective with just a single dose," said Nessan Bermingham, Ph.D., chief executive officer, and founder, Intellia Therapeutics. "We expect to advance preclinical studies significantly this year by progressing our technology in non-human primate studies and look toward its potential broad clinical applications to help treat patients with unmet medical needs."